Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Strategic Value of Product Forecasting Is Critical: Dr Ramsey of Mattson Jack Group
March 12, 2001
- Chugai Forms Functional Genomics Alliance with Immusol
March 12, 2001
- Domestic Market for CRO Business Estimated to Be \150 Bil.: CMIC President
March 12, 2001
- Next-generation Vitamin D Expected to Be Effective for Colon Cancer: Chugai Seminar
March 12, 2001
- IFPMA Creates Task Force on Access to Anti-AIDS Drugs
March 12, 2001
- Actelion to Launch First Endothelin Receptor Antagonists: JPLA Meeting
March 12, 2001
- Mitsubishi Chemical, Fujitsu Tie Up for Bioinformatics
March 12, 2001
- MEDICAL DEVICE NEWS IN BRIEF
March 12, 2001
- Tanabe Licenses PDE5 Inhibitor to Vivus
March 12, 2001
- Panic Disorder Is Curable by Drug Therapy: GSK Seminar
March 12, 2001
- WORLD BUSINESS NEWS IN BRIEF
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -1-
March 12, 2001
- BUSINESS NEWS IN BRIEF -1-
March 12, 2001
- Nomura BioConference Focuses on Latest Biotechnology -2-
March 12, 2001
- Elsevier Science Acquires MIX
March 12, 2001
- Hitachi Spins Off Instruments, Semiconductor Manufacturing Equipment Businesses
March 12, 2001
- Maruishi: Sevofrane Pushes Sales to \32 Bil., Up 6.4%
March 12, 2001
- Mitsubishi Ties Up with TeraRecon in 3D Graphics Business
March 12, 2001
- Approval of 8 New Drugs Including Radicut, Fiblast Spray Granted
March 12, 2001
- DIAGNOSTIC NEWS IN BRIEF
March 12, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…